Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Seely

Interventional Pain Medicine Jackson, TN Medical Doctor

NPI 1609163880 CMS profile 1149195

219 Stonebridge Blvd, Jackson, TN 38305

Open in the dashboard

General payments

$8,588

171 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Seely of Jackson, TN is reported in the CMS Open Payments database as having received $8,588 across 171 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $940 32
2024 General $2,838 31
2023 General $1,673 39
2022 General $370 17
2021 General $2,124 22
2020 General $175 12
2019 General $469 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Seely
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to William Seely were reported at $940. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year William Seely Interventional Pain Medicine median Middle half National median
2019 $469 $684 $216–$2,079 $163
2020 $175 $382 $122–$1,109 $114
2021 $2,124 $552 $167–$1,554 $132
2022 $370 $605 $187–$1,924 $149
2023 $1,673 $671 $195–$1,915 $160
2024 $2,838 $684 $206–$1,837 $164
2025 $940 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $5,437 91 payments
  2. Nalu Medical, Inc. $1,001 11 payments
  3. Abbott Laboratories $631 16 payments
  4. SPR Therapeutics, Inc $411 7 payments
  5. Medtronic, Inc. $155 5 payments
  6. Vertos Medical, Inc. $126 6 payments
  7. Flowonix Medical Incorporated $106 1 payment
  8. Foundation Fusion Solutions, LLC $101 1 payment
  9. Collegium Pharmaceutical, Inc. $73 5 payments
  10. Innovation Technologies Inc $56 2 payments
  11. Other $490 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,753 157 payments
  2. Travel and Lodging $3,729 13 payments
  3. Entertainment $106 1 payment
Products named General payments · program years 2019–2025
  1. Superion $1,082 6 payments
  2. Nalu Neurostimulation System $1,001 11 payments
  3. WaveWriter Alpha Prime 16 $870 37 payments
  4. VERTIFLEX SUPERION $767 4 payments
  5. SPRINT PNS System $411 7 payments
  6. PROCLAIM Neuromodulation $303 7 payments
  7. GENERAL PAIN MANAGEMENT $274 11 payments
  8. PROCLAIM Neuromodulation $145 4 payments
  9. mild Device Kit $126 6 payments
  10. INTELLIS ADAPTIVESTIM $119 2 payments
  11. Other $1,495 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

2,913

Median for Interventional Pain Management: 1,220

Drug cost

$29,950

Median for Interventional Pain Management: $39,344

Branded share of claims

10.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 769 $10,461
Pregabalin Generic 317 $6,487
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 244 $2,847
Buprenorphine Generic 18 $2,624
Tramadol Hcl Generic 601 $2,482
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 60 $1,161
Diclofenac Sodium Generic 53 $736
Baclofen Generic 103 $736
Duloxetine Hcl Generic 47 $576
Tizanidine Hcl Generic 36 $478

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$342,549

Of which drugs: $5,577

Medicare patients

870

Average age 74

Services billed

31,046

530 women, 340 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 31%
Chronic kidney disease 27%
Depression 26%
Atrial fibrillation 19%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 324 25,124 $2,545
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 40 230 $1,193
Injection, methylprednisolone acetate, 80 mg J1040 Office 155 161 $1,048
Injection, methylprednisolone acetate, 40 mg J1030 Office 43 61 $303
Injection, ketorolac tromethamine, per 15 mg J1885 Office 84 470 $259
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 129 1,718 $149
Injection, fentanyl citrate, 0.1 mg J3010 Office 20 34 $24
Injection, midazolam hydrochloride, per 1 mg J2250 Office 30 85 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $20
$20 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

171 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record